Tetra-modality bladder preservation with avelumab for muscle-invasive urothelial cancer: a phase II trial (TRIUMPH-B01).
Ali Shamseddine, Noura Abbas, Sally Temraz...
https://pubmed.ncbi.nlm.nih.gov/40851456/Actively Recruiting
Led by American University of Beirut Medical Center · Updated on 2026-10-29
80
Participants Needed
1
Research Sites
2 weeks
Total Duration
This trial is investigating treatments for muscle-invasive bladder cancer MIBC, an aggressive type of bladder cancer with a 5-year survival rate of about 40%. The study aims to assess the safety and effectiveness of adding the immunotherapy drug Avelumab to standard bladder preservation methods, comparing two multi-step treatment plans to increase the chance of keeping the bladder intact and reduce the need for bladder removal surgery. Both treatment strategies are designed to explore a combination of tumor removal, chemotherapy, radiation, and immunotherapy. Participants receive one of two treatment plans. Both start with maximum tumor removal through TURBT, followed by induction chemotherapy combined with Avelumab immunotherapy. After this, patients undergo radiation therapy. In one plan, patients continue with Avelumab maintenance every two weeks for 12 months. In the other plan, patients enter a watch-and-wait phase for one year instead of maintenance therapy. The total duration for these treatments can last up to two years from when participants join the study. Throughout the trial, participants undergo clinical evaluations including CT or MRI scans of the chest, abdomen, and pelvis, cystoscopy with biopsy, and urine cytology at four months after starting induction therapy. Quality of life and safety assessments are conducted regularly during treatment and follow-up. The main outcome measured is the proportion of patients who avoid bladder removal surgery two years after treatment begins. This study is sponsored by the American University of Beirut Medical Center and includes ongoing monitoring of response rates and adverse effects.
CONDITIONS
Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W
A
Ali I. Shamseddine, MD, FRCP, ESCO
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
American University of Beirut Medical Center
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Duration - Approximately 4 months
Participants undergo maximum tumor removal followed by chemotherapy combined with Avelumab immunotherapy for induction.
Regular visits for chemotherapy and immunotherapy cycles
Duration - Several weeks following induction treatment
Participants receive 20 fractions of hypo-fractionated radiotherapy targeting the bladder area.
Multiple radiation therapy sessions
Duration - Up to 12 months
Participants either receive Avelumab every two weeks for 12 months as maintenance therapy or enter a watch-and-wait phase for one year with supportive care.
Scheduled visits every two weeks for maintenance or periodic monitoring during watch and wait
Duration - Up to 2 years from study inclusion
Participants undergo clinical evaluations including imaging, cystoscopy with biopsy, and urine tests to monitor cancer status and quality of life.
Scheduled assessments at 4 months post-induction and periodic follow-ups
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Ali Shamseddine, Noura Abbas, Sally Temraz...
https://pubmed.ncbi.nlm.nih.gov/40851456/American University of Beirut Medical Center
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Collaborating Sponsor